Clinicopathological and Prognostic Values of Gankyrin, Snail۱, and IDH۱ Expression in Renal Cell Carcinoma Patients

سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 283

فایل این مقاله در 10 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_MISJ-13-2_004

تاریخ نمایه سازی: 25 آبان 1402

چکیده مقاله:

Background: Gankyrin is an oncoprotein incriminated in cancer growth, invasion, and spread. Snail۱ is associated with mesenchymal features acquisition that is related to invasion and metastasis of malignant cells. Isocitrate dehydrogenase ۱(IDH۱) has been found to be mutated in several cancers, which leads to altered cellular metabolism and tumorgenesis. The present study aimed to assess Gankyrin, Snail۱, and IDH۱ expression patterns and compare them to clinicopathological and prognostic parameters.Method: In our prospective cohort study, the samples taken from ۶۰ renal cell carcinoma (RCC) patients were processed, diagnosed, graded, staged, and subjected to immunohistochemistry for Gankyrin, Snail۱, and IDH۱. The patients were chosen, treated, and followed up from January ۲۰۱۵ to December ۲۰۱۹. Overall survival (OS) and progression-free survival (PFS) were assessed.Results: High expression levels of Gankyrin were positively associated with high grade (P = ۰.۰۰۳), stage (P = ۰.۰۳۳), and size of the tumor (P = ۰.۰۴۹), in addition to lymph nodes metastasis (P = ۰.۰۱), distant metastases (P = ۰.۰۰۷), higher incidence of tumor progression, unfavorable ۵-year PFS, and OS rates (P < ۰.۰۰۱). High expression levels of Snail۱ were positively associated with high grade (P = ۰.۰۰۴) and stage (P = ۰.۰۲۳) of the tumors, on top of lymph nodes metastasis (P = ۰.۰۰۳), distant metastases (P = ۰.۰۰۲), higher incidence of tumor progression, poorer fiveyear PFS, and OS rates (P < ۰.۰۰۱). High expression levels of IDH۱ were negatively associated with low grade (P = ۰.۰۰۲), stage, and size of the tumor and lymph nodes metastasis (P < ۰.۰۰۱), distant metastases (P = ۰.۰۴۱), lower incidence of tumor progression (P = ۰.۰۱۳), better five-year PFS, and OS rates (P < ۰.۰۴۱).Conclusion: We indicated the associations between poor RCC pathological parameters, unfavorable patients’ outcome, high Gankyrin, high Snail۱, and reduced IDH۱ expression.

نویسندگان

Randa Kaf

Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Ola Harb

Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Magid Ali

Department of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Nashaat Salama

Department of Urology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Taha Baiomy

Department of General Surgery, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Marwa Abdelgawad

Department of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt

Lobna Abdelaziz

Department of Clinical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer ...
  • Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal ...
  • Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. ...
  • Wang C, Li Y, Chu CM, Zhang XM, Ma J, ...
  • Chen J, Bai M, Ning C, Xie B, Zhang J, ...
  • Meng FD, Li Y, Tian X, Ma P, Sui CG, ...
  • Andreina BC, Stepan AE, Margaritescu C, Tăisescu O, Osman A, ...
  • Laba PL, Wang J, Zhang J. Low level of isocitrate ...
  • Edges SB, Compton CC. The American joint committee on Cancer: ...
  • Delahunt B, Srigley JR, Egevad L, Montironi R. International Society ...
  • Wang C, Cheng L. Gankyrin as a potential therapeutic target ...
  • Huang B, Cai W, Wang Q, Shah ET, He Y, ...
  • Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, ...
  • Sheng Y, Ng CP, Lourie R, Shah ET, He Y, ...
  • Liu Y, Higashitsuji H , Higashitsuji H, Itoh K, Sakurai ...
  • Chapman AM, McNaughton BR. Synthetic proteins potently and selectively bind ...
  • Song X, Wang J, Zheng T, Song R, Liang Y, ...
  • Chattopadhyay A , O'Connor CJ, Zhang F, Galvagnion C, Galloway ...
  • Mikami S, Katsube KI, Oya M, Ishida M, Kosaka T, ...
  • O'Mahony FC, Faratian D, Varley J, Nanda J, Theodoulou M, ...
  • Cai J. Roles of transcriptional factor Snail and adhesion factor ...
  • Liu W, Liu Y, Liu H, Zhang W, An H, ...
  • Messai Y, Noman MZ, Derouiche A, Kourda N, Akalay I, ...
  • Liu WS, Chan SH, Chang HT, Li GC, Tu YT, ...
  • Zhao S, Lin Y, Xu W, Jiang W, Zha Z, ...
  • Chen X , Li Q, Wang C, Xu W, Han ...
  • Waitkus MS, Diplas BH, Yan H. Isocitrate dehydrogenase mutations in ...
  • Nassereddine S, Lap CJ, Haroun F, Tabbara I. The role ...
  • Bogdanovic E. IDH۱ lipid metabolism and cancer: shedding new light ...
  • Lu J, Holmgren A. Thioredoxin system in cell death progression. ...
  • Dang L, Yen K, Attar EC. IDH mutations in cancer ...
  • نمایش کامل مراجع